Updated:
Apeiron Investment Group
Angermayer launched Apeiron Investment Group in 2015 as the primary vehicle for his entrepreneurial and investment activities, headquartered in Malta with...
Apeiron Investment Group
Angermayer launched Apeiron Investment Group in 2015 as the primary vehicle for his entrepreneurial and investment activities, headquartered in Malta with additional offices in New York, London, Berlin, and Abu Dhabi. The firm manages both internal family capital and external investor funds, reportedly totaling roughly $7 billion, deploying across the full company lifecycle. Apeiron's strategy mixes direct balance-sheet investments with anchor LP positions and GP stakes in emerging asset managers, creating a hybrid structure uncommon among single-family offices. The firm has concentrated its portfolio in biotech, fintech and crypto, deep tech, and experiences, hospitality, and sports, alongside opportunistic plays in real estate and natural resources. Confirmed positions include atai Life Sciences, a psychedelic-medicine platform, and Samara Asset Group, the crypto-focused vehicle co-founded with Mike Novogratz. The firm invests across the US, Europe, and the Middle East, with early-stage through growth-stage mandates. The firm does not publicly disclose its total headcount, though teams operate across five cities on three continents. Apeiron's reach extends beyond investing into policy and advocacy through the Angermayer Policy and Innovation Institute and the AURORA Institute, and its founder participates in the World Economic Forum as a Young Global Leader and the Milken Institute's Young Leaders Circle. In May 2024, Christian Angermayer raised his profile as a vocal advocate for psychedelic therapies and longevity science, continuing a multi-year push to mainstream those sectors. Apeiron's structure blurs the line between a single-family office and an institutional asset manager: it runs commingled external capital while retaining the concentrated conviction bets and art-backed cultural branding of a billionaire's private office. That blend — anchored by Angermayer's personal network, which includes long-time co-investor Peter Thiel and an advisory relationship with Rwanda's President Paul Kagame — gives the firm a sourcing and influence edge that pure-fund managers rarely replicate.
General information
Firm type
Single Family Office
Year founded
2015
AUM
~$7B (per firm website, 2025)
Location
Region
Europe
Country
Malta
City
Sliema
Corporate office
Sliema, Malta
Additional offices
New York · London · Berlin · Abu Dhabi
Principals
Christian Angermayer
Founder
Sector focus
Frequently asked questions
Who controls investment decisions at Apeiron?
Christian Angermayer, as founder and sole owner, exercises ultimate discretion over Apeiron's investment strategy and capital allocation. The firm operates as a discretionary vehicle, meaning Angermayer's personal conviction drives the portfolio, though the firm employs teams across New York, London, Berlin, Abu Dhabi, and Malta to execute the mandate.
Does Apeiron manage only Christian Angermayer's personal capital?
No. The firm's website states it manages roughly $7 billion of 'both internal and external capital.' This makes Apeiron a hybrid structure — part family office investing proprietary wealth and part asset manager running commingled funds — distinct from pure single-family offices.
How does Apeiron source its deal flow?
Apeiron's sourcing relies heavily on Angermayer's personal network, including long-time co-investment relationships with Peter Thiel and Mike Novogratz, and his advisory role to Rwanda's President Paul Kagame. The firm also accesses pipeline through its GP stakes in emerging managers and its presence in specialist circles like the Milken Institute and World Economic Forum.
What is Apeiron's relationship with atai Life Sciences?
atai Life Sciences is a core portfolio holding and one of Apeiron's most visible bets. Christian Angermayer co-founded the company and has used Apeiron's balance sheet to anchor its funding rounds, positioning the firm at the center of the psychedelic-medicine renaissance. Peter Thiel has also co-invested alongside Apeiron in atai.
Does Apeiron invest only in biotech and psychedelics?
No. While biotech and psychedelics are the firm's most prominent bets, Apeiron is a generalist investor. Its stated sector focuses include fintech, crypto, deep tech, and experiences and hospitality. The firm also holds real estate assets, natural resources, a significant cryptocurrency position, and an extensive ancient art collection.
How is Apeiron's philanthropic activity structured?
Apeiron maintains two known affiliated nonprofit vehicles: the Angermayer Policy and Innovation Institute and the AURORA Institute. These operate alongside the investment firm, advancing policy work and public advocacy — particularly around psychedelic therapies and human enhancement — consistent with the portfolio's thematic bets.
What region does Apeiron prioritize for investments?
The firm applies a global mandate with a primary focus on the United States, according to its website. It also actively deploys capital in Europe and the Middle East, supported by offices in London, Berlin, and Abu Dhabi, and maintains relationships across Africa through Angermayer's advisory work.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: